Gällande vårdprogram matstrups- ooch magsäckscancer

Fastställt av Regionala cancercentrum i samverkan 2012-03-23

22. Litteraturreferenser

1. Ferlay, J., et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010.

2. Corley, D.A. and P.A. Buffler, Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol, 2001. 30(6): p. 1415-25.

3. Enzinger, P.C. and R.J. Mayer, Esophageal cancer. N Engl J Med, 2003. 349(23): p. 2241-52.

4. Cook, M.B., W.H. Chow, and S.S. Devesa, Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer, 2009. 101(5): p. 855-9.

5. Devesa, S.S., W.J. Blot, and J.F. Fraumeni, Jr., Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer, 1998. 83(10): p. 2049-53.

6. Cancer Statistics Sweden 1958-2009. The National Board of Health and Welfare, 2011.

7. Ginsberg, G.F., DE., Esophageal tumors. In: Feldman M, Friedman, L.S., Sleisenger, M.H., ed. Sleisenger & Fordtran´s Gastrointestinal and Liver Disease. Philadelphia: Saunders, 2002, 2002. Volume 1, 7th ed.: p. 647-671.

8. Prach, A.T., et al., Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet, 1997. 350(9082): p. 933.

9. Lauren, P., The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand, 1965. 64: p. 31-49.

10. Correa, P. and Y.H. Shiao, Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res, 1994. 54(7 Suppl): p. 1941s-1943s.

11. Koh, T., Wang, TC., Tumors of the Stomach. In: Feldman M, Friedman, L.S., Sleisenger, M.H., ed. Sleisenger´s & Fordtran´s Gastrointestinal and Liver Disease. Philadelphia: Saunders, 2002, 2002. Volume 1, 7 th ed.: p. 829-855.

12. Vaughan, T.L., et al., Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev, 1995. 4(2): p. 85-92.

13. Lagergren, J., et al., The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer, 2000. 85(3): p. 340-6.

14. Chow, W.H., et al., The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA, 1995. 274(6): p. 474-7.

15. Lagergren, J., et al., Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med, 1999. 340(11): p. 825-31.

16. Farrow, D.C., et al., Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control, 2000. 11(3): p. 231-8.

17. Gammon, M.D., et al., Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst, 1997. 89(17): p. 1277-84.

18. Wu, A.H., P. Wan, and L. Bernstein, A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control, 2001. 12(8): p. 721-32.

19. Chow, W.H., et al., An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res, 1998. 58(4): p. 588-90.

20. Ye, W., et al., Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst, 2004. 96(5): p. 388-96.

21. IARC, Infection with Helicobacter pylori. In: Shistosomes, liver flukes and Helicobacter pylori, in IARC monographs on the evaluation of carcinogenic risks to humans., IARC, Editor. 1994, IARC: Lyon. p. 177-202.

22. Parkin, D.M., Global cancer statistics in the year 2000. Lancet Oncology, 2001. 2(9): p. 533-43.

23. Sundelof, M., et al., Improved survival in both histologic types of oesophageal cancer in Sweden. Int J Cancer, 2002. 99(5): p. 751-4.

24. Rouvelas, I., et al., Survival after surgery for oesophageal cancer: a population-based study. Lancet Oncol, 2005. 6(11): p. 864-70.

25. Lepage, C., et al., Operative mortality after gastric cancer resection and long-term survival differences across Europe. Br J Surg, 2010. 97(2): p. 235-9.

26. Rouvelas, I. and J. Lagergren, The impact of volume on outcomes after oesophageal cancer surgery. ANZ J Surg, 2010. 80(9): p. 634-41.

27. Sant, M., et al., EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer, 2009. 45(6): p. 931-91.

28. Wouters, M.W., et al., Centralization of esophageal cancer surgery: does it improve clinical outcome? Ann Surg Oncol, 2009. 16(7): p. 1789-98.

29. Finks, J.F., N.H. Osborne, and J.D. Birkmeyer, Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med, 2011. 364(22): p. 2128-37.

30. Lagergren, J. and P. Lagergren, Oesophageal cancer. BMJ, 2010. 341: p. c6280.

31. Lagergren, J., et al., Utility of endoscopic screening for upper gastrointestinal adenocarcinoma. JAMA, 2000. 284(8): p. 961-2.

32. Anderson, L., Murphy SJ, Johnston BT, Watson RG, Ferguson HR, Bamford KB, Relationship between Helicobacter pylori infection and gastrid atrophy and the stages of the oesophageal infalmmation, metaplasia, adenocarcinom sequence: results from the FINBAR casecontrol study. Gut, 2008. 57:734-9.

33. Rokkas, T., et al., Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol, 2007. 5(12): p. 1413-7, 1417 e1-2.

34. Stewart, B., Kleihues, P, World Cancer Report. Lyon IARC Press, 2003.

35. Fuccio, L., L.H. Eusebi, and F. Bazzoli, Gastric cancer, Helicobacter pylori infection and other risk factors. World J Gastrointest Oncol, 2010. 2(9): p. 342-7.

36. IARC, International Agency for Research on Cancer. Schistosomes, , 1994.

37. Fock, K.M., et al., Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol, 2008. 23(3): p. 351-65.

38. Wong, R.H., et al., Actinomycosis: an often forgotten diagnosis. Asian Cardiovasc Thorac Ann, 2004. 12(2): p. 165-7.

39. Asaka, M., M. Kato, and D.Y. Graham, Prevention of gastric cancer by Helicobacter pylori eradication. Intern Med, 2010. 49(7): p. 633-6.

40. Malfertheiner, P., Helicobacter pylori--a timeless source of lessons and research initiatives. Helicobacter, 2007. 12 Suppl 2: p. 85-9.

41. Rubenstein, J.H., et al., Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc, 2008. 68(5): p. 849-55.

42. Okines, A., et al., Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2010. 21 Suppl 5: p. v50-4.

43. Tentzeris, V., et al., Poor awareness of symptoms of oesophageal cancer. Interact CardioVasc Thorac Surg, 2011. 12(1): p. 32-34.

44. Schwartz, S.I., ed. Principles of Surgery 6th edition ed. 1994, McGraw-Hill: Rochester, USA.

45. Gallo, A. and C. Cha, Updates on esophageal and gastric cancers. World J Gastroenterol, 2006. 12(20): p. 3237-42.

46. Gibbs, J.F., et al., The changing profile of esophageal cancer presentation and its implication for diagnosis. J Natl Med Assoc, 2007. 99(6): p. 620-6.

47. Ergul, E. and E.O. Gozetlik, Emergency spontaneous gastric perforations: ulcus versus cancer. Langenbecks Arch Surg, 2009. 394(4): p. 643-6.

48. Fuchs, C.S. and R.J. Mayer, Gastric carcinoma. N Engl J Med, 1995. 333(1): p. 32-41.

49. Riddell, R.H., et al., Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol, 1983. 14(11): p. 931-68.

50. Wang, K.K. and R.E. Sampliner, Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol, 2008. 103(3): p. 788-97.

51. Shi, X.Y., B. Bhagwandeen, and A.S. Leong, p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus. Appl Immunohistochem Mol Morphol, 2008. 16(5): p. 447-52.

52. Dorer, R. and R.D. Odze, AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am J Surg Pathol, 2006. 30(7): p. 871-7.

53. Souza, R.F., Biomarkers in Barrett's Esophagus. Tech Gastrointest Endosc, 2010. 12(2): p. 116-1212.

54. Bosman, F.T.C., F. Hruban, RH, Theise, ND, WHO classification of tumours of the digestive system. 4th Edition. Lyon IARC Press, 2010.

55. Sobin, L., M. Gospodarowicz, and C. Wittekind, TNM classification of malignant tumours. 7 ed. Oxford: Wiley-Blackwell, 2009.

56. Wind, J., et al., A systematic review on the significance of extracapsular lymph node involvement in gastrointestinal malignancies. Eur J Surg Oncol, 2007. 33(4): p. 401-8.

57. D'Journo, X.B., et al., Extracapsular lymph node involvement is a negative prognostic factor after neoadjuvant chemoradiotherapy in locally advanced esophageal cancer. J Thorac Oncol, 2009. 4(4): p. 534-9.

58. Chang, F., et al., Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: practical guidelines and current issues. Am J Clin Pathol, 2008. 129(2): p. 252-62.

59. Wu, T.T., et al., Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol, 2007. 31(1): p. 58-64.

60. Berger, A.C., et al., Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol, 2005. 23(19): p. 4330-7.

61. Mansour, J.C., et al., Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol, 2007. 14(12): p. 3412-8.

62. Keulers, B.J., et al., Surgeons underestimate their patients' desire for preoperative information. World J Surg, 2008. 32(6): p. 964-70.

63. Lithner, M. and T. Zilling, Does preoperative information increase the wellbeing of the patient after surgery? (in Swedish). Vård i Norden 1998; 18:31-33,39, 1998.

64. Burney, M., M. Purden, and L. McVey, Patient satisfaction and nurses' perceptions of quality in an inpatient cardiology population. J Nurs Care Qual, 2002. 16(4): p. 56-67; quiz 68-9.

65. Jones, K.R., R.E. Burney, and B. Christy, Patient expectations for surgery: are they being met? Jt Comm J Qual Improv, 2000. 26(6): p. 349-60.

66. Lithner, M. and T. Zilling, Pre- and postoperative information needs. Patient Educ Couns, 2000. 40(1): p. 29-37.

67. Reiner, B., et al., The impact of routine CT of the chest on the diagnosis and management of newly diagnosed squamous cell carcinoma of the head and neck. AJR Am J Roentgenol, 1997. 169(3): p. 667-71.

68. Vikgren, J., et al., Comparison of chest tomosynthesis and chest radiography for detection of pulmonary nodules: human observer study of clinical cases. Radiology, 2008. 249(3): p. 1034-41.

69. van Vliet, E.P., et al., Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer, 2008. 98(3): p. 547-57.

70. van Vliet, E.P., et al., Radiologist experience and CT examination quality determine metastasis detection in patients with esophageal or gastric cardia cancer. Eur Radiol, 2008. 18(11): p. 2475-84.

71. Hwang, S.W., et al., Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol, 2010. 25(3): p. 512-8.

72. Lee, I.J., et al., Diagnostic performance of 64-channel multidetector CT in the evaluation of gastric cancer: differentiation of mucosal cancer (T1a) from submucosal involvement (T1b and T2). Radiology, 2010. 255(3): p. 805-14.

73. Moschetta, M., et al., Preoperative T staging of gastric carcinoma obtained by MDCT vessel probe reconstructions and correlations with histological findings. Eur Radiol, 2010. 20(1): p. 138-45.

74. Pan, Z., et al., Determining gastric cancer resectability by dynamic MDCT. Eur Radiol, 2010. 20(3): p. 613-20.

75. Takizawa, K., et al., Lymph node staging in esophageal squamous cell carcinoma: a comparative study of endoscopic ultrasonography versus computed tomography. J Gastroenterol Hepatol, 2009. 24(10): p. 1687-91.

76. van Vliet, E.P., et al., Detection of distant metastases in patients with oesophageal or gastric cardia cancer: a diagnostic decision analysis. Br J Cancer, 2007. 97(7): p. 868-76.

77. Hanamiya, M., et al., Frequency and significance of pulmonary nodules on thin-section CT in patients with extrapulmonary malignant neoplasms. Eur J Radiol, 2010.

78. Quint, L.E., C.H. Park, and M.D. Iannettoni, Solitary pulmonary nodules in patients with extrapulmonary neoplasms. Radiology, 2000. 217(1): p. 257-61.

79. Niekel, M.C., S. Bipat, and J. Stoker, Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology, 2010. 257(3): p. 674-84.

80. Riddell, A.M., et al., The appearances of oesophageal carcinoma demonstrated on high-resolution, T2-weighted MRI, with histopathological correlation. Eur Radiol, 2007. 17(2): p. 391-9.

81. Anzidei, M., et al., Diagnostic performance of 64-MDCT and 1.5-T MRI with high-resolution sequences in the T staging of gastric cancer: a comparative analysis with histopathology. Radiol Med, 2009. 114(7): p. 1065-79.

82. Tatsumi, Y., et al., Preoperative diagnosis of lymph node metastases in gastric cancer by magnetic resonance imaging with ferumoxtran-10. Gastric Cancer, 2006. 9(2): p. 120-8.

83. Nishimura, H., et al., Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10, an ultrasmall superparamagnetic iron oxide. J Am Coll Surg, 2006. 202(4): p. 604-11.

84. Cabassa, P., et al., Liver metastases: Sulphur hexafluoride-enhanced ultrasonography for lesion detection: a systematic review. Ultrasound Med Biol, 2010. 36(10): p. 1561-7.

85. Sim, S.H., et al., The role of PET/CT in detection of gastric cancer recurrence. BMC Cancer, 2009. 9: p. 73.

86. Kim, S.J., et al., Peritoneal metastasis: detection with 16- or 64-detector row CT in patients undergoing surgery for gastric cancer. Radiology, 2009. 253(2): p. 407-15.

87. van Heijl, M., et al., Diagnostic strategies for pre-treatment staging of patients with oesophageal cancer. Dig Surg, 2009. 26(2): p. 149-55.

88. Schreurs, L.M., et al., Current relevance of cervical ultrasonography in staging cancer of the esophagus and gastroesophageal junction. Eur J Radiol, 2008. 67(1): p. 105-11.

89. Gabrielsen, T.O., et al., Esophageal carcinoma metastatic to the brain: clinical value and cost-effectiveness of routine enhanced head CT before esophagectomy. AJNR Am J Neuroradiol, 1995. 16(9): p. 1915-21.

90. Himeno, S., et al., Evaluation of esophageal cancer by positron emission tomography. Jpn J Clin Oncol, 2002. 32(9): p. 340-6.

91. Kato, H., et al., The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer, 2005. 103(1): p. 148-56.

92. Mamede, M., et al., Pre-operative estimation of esophageal tumor metabolic length in FDG-PET images with surgical pathology confirmation. Ann Nucl Med, 2007. 21(10): p. 553-62.

93. Zhong, X., et al., Using 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys, 2009. 73(1): p. 136-41.

94. van Westreenen, H.L., et al., Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol, 2004. 22(18): p. 3805-12.

95. Imdahl, A., et al., Impact of FDG-PET for staging of oesophageal cancer. Langenbecks Arch Surg, 2004. 389(4): p. 283-8.

96. Katsoulis, I.E., et al., Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study. Int J Surg, 2007. 5(6): p. 399-403.

97. Noble, F., et al., Impact of integrated PET/CT in the staging of oesophageal cancer: a UK population-based cohort study. Clin Radiol, 2009. 64(7): p. 699-705.

98. Flamen, P., et al., The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg, 2000. 120(6): p. 1085-92.

99. Guo, H., et al., Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus. J Nucl Med, 2007. 48(8): p. 1251-8.

100. Sun, L., et al., Clinical usefulness of 18F-FDG PET/CT in the restaging of esophageal cancer after surgical resection and radiotherapy. World J Gastroenterol, 2009. 15(15): p. 1836-42.

101. Teyton, P., et al., Use of positron emission tomography in surgery follow-up of esophageal cancer. J Gastrointest Surg, 2009. 13(3): p. 451-8.

102. Javeri, H., et al., The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer, 2009. 115(22): p. 5184-92.

103. Lordick, F., et al., PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncology, 2007. 8(9): p. 797-805.

104. Swisher, S.G., et al., 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer, 2004. 101(8): p. 1776-85.

105. Smithers, B.M., et al., Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Dis Esophagus, 2008. 21(2): p. 151-8.

106. Vallbohmer, D., et al., [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg, 2009. 250(6): p. 888-94.

107. Schmidt, M., et al., Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging, 2009. 36(5): p. 735-44.

108. Roedl, J.B., et al., Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol, 2008. 89(3): p. 278-86.

109. Roedl, J.B., et al., Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography. Ann Thorac Surg, 2008. 86(4): p. 1131-8.

110. Kwee, R.M., Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology, 2010. 254(3): p. 707-17.

111. Ngamruengphong, S., et al., Assessment of response to neoadjuvant therapy in esophageal cancer: an updated systematic review of diagnostic accuracy of endoscopic ultrasonography and fluorodeoxyglucose positron emission tomography. Dis Esophagus, 2010. 23(3): p. 216-31.

112. Suttie, S.A., A.E. Welch, and K.G. Park, Positron emission tomography for monitoring response to neoadjuvant therapy in patients with oesophageal and gastro-oesophageal junction carcinoma. Eur J Surg Oncol, 2009. 35(10): p. 1019-29.

113. Westerterp, M., et al., Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review. Radiology, 2005. 236(3): p. 841-51.

114. Rizk, N., et al., Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg, 2006. 81(3): p. 1076-81.

115. Sepesi, B., et al., Does the value of PET-CT extend beyond pretreatment staging? An analysis of survival in surgical patients with esophageal cancer. J Gastrointest Surg, 2009. 13(12): p. 2121-7.

116. Shenfine, J., et al., Prognostic value of maximum standardized uptake values from preoperative positron emission tomography in resectable adenocarcinoma of the esophagus treated by surgery alone. Dis Esophagus, 2009. 22(8): p. 668-75.

117. van Heijl, M., et al., Influence of ROI definition, partial volume correction and SUV normalization on SUV-survival correlation in oesophageal cancer. Nucl Med Commun, 2010. 31(7): p. 652-8.

118. Rizk, N.P., et al., Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol, 2009. 4(7): p. 875-9.

119. Pan, L., et al., Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol, 2009. 21(9): p. 1008-15.

120. Leong, T., et al., A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol, 2006. 78(3): p. 254-61.

121. Moureau-Zabotto, L., et al., Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. Int J Radiat Oncol Biol Phys, 2005. 63(2): p. 340-5.

122. Schreurs, L.M., et al., Impact of 18-fluorodeoxyglucose positron emission tomography on computed tomography defined target volumes in radiation treatment planning of esophageal cancer: reduction in geographic misses with equal inter-observer variability: PET/CT improves esophageal target definition. Dis Esophagus, 2010. 23(6): p. 493-501.

123. Muijs, C.T., et al., Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer. Radiother Oncol, 2009. 93(3): p. 447-53.

124. Dassen, A.E., et al., FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol, 2009. 35(5): p. 449-55.

125. Kwee, R.M. and T.C. Kwee, Imaging in assessing lymph node status in gastric cancer. Gastric Cancer, 2009. 12(1): p. 6-22.

126. Hur, H., et al., The efficacy of preoperative PET/CT for prediction of curability in surgery for locally advanced gastric carcinoma. World J Surg Oncol, 2010. 8: p. 86.

127. Yoshioka, T., et al., Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med, 2003. 44(5): p. 690-9.

128. Kinkel, K., et al., Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology, 2002. 224(3): p. 748-56.

129. Bilici, A., et al., The role of (1)F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making? Eur J Nucl Med Mol Imaging, 2011. 38(1): p. 64-73.

130. De Potter, T., et al., Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging, 2002. 29(4): p. 525-9.

131. Nakamoto, Y., et al., Clinical value of whole-body FDG-PET for recurrent gastric cancer: a multicenter study. Jpn J Clin Oncol, 2009. 39(5): p. 297-302.

132. Park, M.J., et al., Detecting recurrence of gastric cancer: the value of FDG PET/CT. Abdom Imaging, 2009. 34(4): p. 441-7.

133. Di Fabio, F., et al., The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer, 2007. 10(4): p. 221-7.

134. Ott, K., et al., Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol, 2003. 21(24): p. 4604-10.

135. Vallbohmer, D., et al., [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol, 2010. 102(2): p. 135-40.

136. Chung, H.W., et al., High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma. J Cancer Res Clin Oncol, 2010. 136(12): p. 1929-35.

137. Graham, D.Y., et al., Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology, 1982. 82(2): p. 228-31.

138. Sharma, P., et al., The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology, 2006. 131(5): p. 1392-9.

139. Ngamruengphong, S., V.K. Sharma, and A. Das, Diagnostic yield of methylene blue chromoendoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett's esophagus: a meta-analysis. Gastrointest Endosc, 2009. 69(6): p. 1021-8.

140. Pohl, J., et al., Incidence of macroscopically occult neoplasias in Barrett's esophagus: are random biopsies dispensable in the era of advanced endoscopic imaging? Am J Gastroenterol, 2010. 105(11): p. 2350-6.

141. Mannath, J., et al., Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barrett's esophagus: a meta-analysis. Endoscopy, 2010. 42(5): p. 351-9.

142. Curvers, W.L., et al., Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett's esophagus. Gastroenterology, 2010. 139(4): p. 1106-14.

143. Curvers, W.L., et al., Endoscopic trimodal imaging versus standard video endoscopy for detection of early Barrett's neoplasia: a multicenter, randomized, crossover study in general practice. Gastrointest Endosc, 2011. 73(2): p. 195-203.

144. Mannath, J. and K. Ragunath, Era of Barrett's surveillance: does equipment matter? World J Gastroenterol, 2010. 16(37): p. 4640-5.

145. Update on the paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy, 2005. 37(6): p. 570-8.

146. Dubuc, J., et al., Endoscopic screening for esophageal squamous-cell carcinoma in high-risk patients: a prospective study conducted in 62 French endoscopy centers. Endoscopy, 2006. 38(7): p. 690-5.

147. Muto, M., et al., Early detection of superficial squamous cell carcinoma in the head and neck region and esophagus by narrow band imaging: a multicenter randomized controlled trial. J Clin Oncol, 2010. 28(9): p. 1566-72.

148. May, A., et al., Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial. Gut, 2004. 53(5): p. 634-40.

149. Polkowski, M., Endosonographic staging of upper intestinal malignancy. Best Pract Res Clin Gastroenterol, 2009. 23(5): p. 649-61.

150. Pech, O., et al., Accuracy of endoscopic ultrasound in preoperative staging of esophageal cancer: results from a referral center for early esophageal cancer. Endoscopy, 2010. 42(6): p. 456-61.

151. Shimoyama, S., et al., Accuracy of linear-array EUS for preoperative staging of gastric cardia cancer. Gastrointest Endosc, 2004. 60(1): p. 50-5.

152. Pech, O., E. Gunter, and C. Ell, Endosonography of high-grade intra-epithelial neoplasia/early cancer. Best Pract Res Clin Gastroenterol, 2009. 23(5): p. 639-47.

153. Hassan, H., P. Vilmann, and V. Sharma, Impact of EUS-guided FNA on management of gastric carcinoma. Gastrointest Endosc, 2010. 71(3): p. 500-4.

154. Cheifetz, R.E. and P.T. Phang, Evaluating learning and knowledge retention after a continuing medical education course on total mesorectal excision for surgeons. Am J Surg, 2006. 191(5): p. 687-90.

155. Sharma, A., et al., Colorectal MDTs: the team's perspective. Colorectal Dis, 2008. 10(1): p. 63-8.

156. Ruhstaller, T., et al., The multidisciplinary meeting: An indispensable aid to communication between different specialities. Eur J Cancer, 2006. 42(15): p. 2459-62.

157. Manual for cancer services. Health LDo, 2004.

158. Improving outcomes in upper gastro- intestinal cancers. The Manual 2001.

159. Allum, W.H., et al., Guidelines for the management of oesophageal and gastric cancer. Gut, 2002. 50 Suppl 5: p. v1-23.

160. Courrech Staal, E.F., et al., Quality-of-care indicators for oesophageal cancer surgery: A review. Eur J Surg Oncol, 2010. 36(11): p. 1035-43.

161. Stephens, M.R., et al., Multidisciplinary team management is associated with improved outcomes after surgery for esophageal cancer. Dis Esophagus, 2006. 19(3): p. 164-71.

162. Clark, G.W., et al., Carcinoma of the oesophagus: the time for a multidiciplinary approach? Surg Oncol, 1996. 5(4): p. 149-64.

163. Davies, A.R., et al., The multidisciplinary team meeting improves staging accuracy and treatment selection for gastro-esophageal cancer. Dis Esophagus, 2006. 19(6): p. 496-503.

164. Borrill, C., et al., Team working and effectiveness in health care. Br J Health Care Manage, 2000.

165. Haward, R.A., Using service guidance to shape the delivery of cancer services: experience in the UK. Br J Cancer, 2003. 89 Suppl 1: p. S12-4.

166. Blazeby, J.M., et al., Analysis of clinical decision-making in multi-disciplinary cancer teams. Ann Oncol, 2006. 17(3): p. 457-60.

167. Piccirillo, J.F., et al., Development of a new head and neck cancer-specific comorbidity index. Arch Otolaryngol Head Neck Surg, 2002. 128(10): p. 1172-9.

168. Sharma, R., K. Shah, and E. Glatstein, www.thelancet.com/oncology2009;10:98-9. 2009.

169. MacDermid, E., et al., Improving patient survival with the colorectal cancer multi-disciplinary team. Colorectal Dis, 2009. 11(3): p. 291-5.

170. Martin, L., et al., Malnutrition after oesophageal cancer surgery in Sweden. Br J Surg, 2007. 94(12): p. 1496-500.

171. Evidence based practice guidelines for the nutritional management of malnutrition in adult patients across the continuum of care. Dietitians Association of Australia, Nutrition and Dietics. 2009.

172. Grotenhuis, B.A., et al., Preoperative risk assessment and prevention of complications in patients with esophageal cancer. J Surg Oncol, 2010. 101(3): p. 270-8.

173. Nutrition support in adults: Oral Nutrition Support, Enteral Tube Feeding and Parenteral Nutrition National Collaborating Centre for Acute Care, National Institute for Health and Clinical, 2006.

174. Bosaeus, I., P. Daneryd, and K. Lundholm, Dietary intake, resting energy expenditure, weight loss and survival in cancer patients. J Nutr, 2002. 132(11 Suppl): p. 3465S-3466S.

175. Tisdale, M.J., Cancer cachexia. Curr Opin Gastroenterol, 2010. 26(2): p. 146-51.

176. Hyltander, A., et al., Beta-adrenoceptor activity and resting energy metabolism in weight losing cancer patients. Eur J Cancer, 2000. 36(3): p. 330-4.

177. Huhmann, M.B. and D.A. August, Nutrition support in surgical oncology. Nutr Clin Pract, 2009. 24(4): p. 520-6.

178. Kondrup, J., et al., ESPEN guidelines for nutrition screening 2002. Clin Nutr, 2003. 22(4): p. 415-21.

179. Stratton, R., C. Green, and E. M., Disease-related malnutrition: an evidence-based approach to treatment. Wallingford: Cabi Publishing, 2003.

180. Stratton, R.J. and M. Elia, Who benefits from nutritional support: what is the evidence? Eur J Gastroenterol Hepatol, 2007. 19(5): p. 353-8.

181. Arends, J., et al., ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr, 2006. 25(2): p. 245-59.

182. Weimann, A., et al., ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation. Clin Nutr, 2006. 25(2): p. 224-44.

183. Cerantola, Y., et al., Immunonutrition in gastrointestinal surgery. Br J Surg, 2011. 98(1): p. 37-48.

184. Cappell, M.S., Risk factors and risk reduction of malignant seeding of the percutaneous endoscopic gastrostomy track from pharyngoesophageal malignancy: a review of all 44 known reported cases. Am J Gastroenterol, 2007. 102(6): p. 1307-11.

185. Morita, M., et al., Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. Int J Clin Oncol, 2010. 15(2): p. 126-34.

186. Lindstrom, D., et al., Effects of a perioperative smoking cessation intervention on postoperative complications: a randomized trial. Ann Surg, 2008. 248(5): p. 739-45.

187. Sadr Azodi, O., et al., The efficacy of a smoking cessation programme in patients undergoing elective surgery: a randomised clinical trial. Anaesthesia, 2009. 64(3): p. 259-65.

188. Tonnesen, H., et al., Effect of preoperative abstinence on poor postoperative outcome in alcohol misusers: randomised controlled trial. BMJ, 1999. 318(7194): p. 1311-6.

189. Ajani, J.A., et al., Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol, 1999. 17(8): p. 2403-11.

190. Ajani, J.A., et al., Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst, 1993. 85(22): p. 1839-44.

191. Ajani, J.A., et al., Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer, 1991. 68(7): p. 1501-6.

192. Crookes, P., et al., Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Cancer, 1997. 79(9): p. 1767-75.

193. Yonemura, Y., et al., Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg, 1993. 17(2): p. 256-61; discussion 261-2.

194. Schuhmacher, C., et al., Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol, 2010. 28(35): p. 5210-8.

195. Ravry MJ, M.M., Omura GA, Esseese I, Bartolucci A., Phase II evaluation of cisplatin in squamous carcinoma of the esophagus: a Southeastern Cancer Study Group trial. Cancer Treat Rep. , 1985. (12)(Dec;69): p. 1457-8.

196.      Bleiberg, H., et al., Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. European Journal of Cancer, 1997. 33(8): p. 1216-1220.

197. Polee, M.B., et al., Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer, 2002. 86(5): p. 669-673.

198. Ilson, D., Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park). 2004. (14 Suppl 14)(Dec;18): p. 22-5.

199. Ajani, J.A., et al., Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial. Journal of Clinical Oncology. 28(9): p. 1547-1553.

200. Cunningham, D., et al., Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 2008. 358(1): p. 36-46.

201. Ross, P., et al., Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol, 2002. 20(8): p. 1996-2004.

202. Al-Batran, S.E., et al., Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol, 2008. 26(9): p. 1435-42.

203. Dank, M., et al., Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol, 2008: p. mdn166.

204. Cunningham, D., et al., Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. New England Journal of Medicine, 2008. 358(1): p. 36-46.

205. Ross, P., et al., Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer. Journal of Clinical Oncology, 2002. 20(8): p. 1996-2004.

206. Al-Batran, S.-E., et al., Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology, 2008. 26(9): p. 1435-1442.

207. Dank, M., et al., Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Annals of Oncology, 2008. 19(8): p. 1450-1457.

208. Bhansali, M.S., et al., Historical control bias: adjuvant chemotherapy in esophageal cancer. Dis Esophagus, 1997. 10(1): p. 51-4.

209. Bhansali, M.S., et al., Chemotherapy for carcinoma of the esophagus: a comparison of evidence from meta-analyses of randomized trials and of historical control studies. Ann Oncol, 1996. 7(4): p. 355-9.

210. Fok, M., et al., Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery, 1993. 113(2): p. 138-47.

211. Tachibana, M., et al., Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial. Eur J Surg Oncol, 2003. 29(7): p. 580-7.

212. Sykes, A.J., et al., Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery. Radiother Oncol, 1998. 48(1): p. 15-21.

213. Xiao, Z.F., et al., Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg, 2003. 75(2): p. 331-6.

214. Arnott, S.J., et al., Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev, 2005(4): p. CD001799.

215. Malthaner, R. and D. Fenlon, Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev, 2003(4): p. CD001556.

216. Allum, W.H., et al., Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol, 2009. 27(30): p. 5062-7.

217. Gebski, V., et al., Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncology, 2007. 8(3): p. 226-34.

218. Sjoquist, K.M., et al., Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncology, 2011. 12(7): p. 681-92.

219. Herskovic, A., et al., Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med, 1992. 326(24): p. 1593-8.

220. Stahl, M., et al., Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol, 2005. 23(10): p. 2310-7.

221. Bedenne, L., et al., Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol, 2007. 25(10): p. 1160-8.

222. Friesland, S., A phase I-II study on treatment with docetaxel in combination with cisplatin, 5-fluorouracil and radiotherapy in patients with locally advanced but not metastatic inoperable oesophageal cancer or cancer in the cardia region. ASCO Gastrointestinal Cancer Symposium, abstract no 44, 2007.

223. Cunningham, D., et al., Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006. 355(1): p. 11-20.

224. Ychou, M., et al., Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol, 2011. 29(13): p. 1715-21.

225. Earle, C.C. and J.A. Maroun, Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer, 1999. 35(7): p. 1059-64.

226. Gianni, L., et al., Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer. Ann Oncol, 2001. 12(8): p. 1178-80.

227. Hermans, J., et al., Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol, 1993. 11(8): p. 1441-7.

228. Mari, E., et al., Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol, 2000. 11(7): p. 837-43.

229. Yao, J.C. and J.A. Ajani, Therapy of localized gastric cancer: preoperative and postoperative approaches. Ann Oncol, 2002. 13 Suppl 4: p. 7-12.

230. Janunger, K.G., et al., A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol, 2001. 40(2-3): p. 309-26.

231.      Sakuramoto, S., et al., Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med, 2007. 357(18): p. 1810-20.

232. Ajani, J.A., et al., Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol, 2010. 28(9): p. 1547-53.

233. Fujimura, T., et al., Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg, 1994. 18(1): p. 150-5.

234. Fujimura, T., et al., [Chemohyperthermic peritoneal perfusion and subtotal peritonectomy for peritonitis carcinomatosa in gastroenteric cancer]. Gan To Kagaku Ryoho, 1995. 22(11): p. 1610-2.

235. Macdonald, J.S., et al., Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 2001. 345(10): p. 725-30.

236. Ajani, J.A., et al., Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol, 2006. 24(24): p. 3953-8.

237. Harrison, J.D., et al., The effect of tamoxifen and estrogen receptor status on survival in gastric carcinoma. Cancer, 1989. 64(5): p. 1007-10.

238. Primrose, J.N., et al., A prospective randomised controlled study of the use of ranitidine in patients with gastric cancer. Yorkshire GI Tumour Group. Gut, 1998. 42(1): p. 17-9.

239. Sakamoto, J., et al., Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials. J Immunother, 2002. 25(5): p. 405-12.

240. Sugarbaker, P.H., W. Yu, and Y. Yonemura, Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol, 2003. 21(4): p. 233-48.

241. Abe, M., Y. Nishimura, and Y. Shibamoto, Intraoperative radiation therapy for gastric cancer. World J Surg, 1995. 19(4): p. 544-7.

242. Sindelar, W.F., et al., Randomized trial of intraoperative radiotherapy in carcinoma of the stomach. Am J Surg, 1993. 165(1): p. 178-86; discussion 186-7.

243. Zingg, U., et al., Risk prediction scores for postoperative mortality after esophagectomy: validation of different models. J Gastrointest Surg, 2009. 13(4): p. 611-8.

244. Kinugasa, S., et al., Postoperative pulmonary complications are associated with worse short- and long-term outcomes after extended esophagectomy. J Surg Oncol, 2004. 88(2): p. 71-7.

245.      Murray, P., et al., Preoperative shuttle walking testing and outcome after oesophagogastrectomy. Br J Anaesth, 2007. 99(6): p. 809-11.

246. Brodner, G., et al., A multimodal approach to control postoperative pathophysiology and rehabilitation in patients undergoing abdominothoracic esophagectomy. Anesth Analg, 1998. 86(2): p. 228-34.

247. Jiang, K., et al., Fast track clinical pathway implications in esophagogastrectomy. World J Gastroenterol, 2009. 15(4): p. 496-501.

248. Low, D.E., et al., Esophagectomy--it's not just about mortality anymore: standardized perioperative clinical pathways improve outcomes in patients with esophageal cancer. J Gastrointest Surg, 2007. 11(11): p. 1395-402; discussion 1402.

249. Flisberg, P., et al., Pain relief after esophagectomy: Thoracic epidural analgesia is better than parenteral opioids. J Cardiothorac Vasc Anesth, 2001. 15(3): p. 282-7.

250.      Rudin, A., et al., Thoracic epidural analgesia or intravenous morphine analgesia after thoracoabdominal esophagectomy: a prospective follow-up of 201 patients. J Cardiothorac Vasc Anesth, 2005. 19(3): p. 350-7.

251. Michelet, P., et al., Effect of thoracic epidural analgesia on gastric blood flow after oesophagectomy. Acta Anaesthesiol Scand, 2007. 51(5): p. 587-94.

252. Michelet, P., et al., Perioperative risk factors for anastomotic leakage after esophagectomy: influence of thoracic epidural analgesia. Chest, 2005. 128(5): p. 3461-6.

253. Cense, H.A., et al., Association of no epidural analgesia with postoperative morbidity and mortality after transthoracic esophageal cancer resection. J Am Coll Surg, 2006. 202(3): p. 395-400.

254. Tachibana, M., et al., One-lung or two-lung ventilation during transthoracic oesophagectomy? Can J Anaesth, 1994. 41(8): p. 710-5.

255. Tsai, J.A., et al., One-lung ventilation during thoracoabdominal esophagectomy elicits complement activation. J Surg Res, 2009. 152(2): p. 331-7.

256. Zingg, U., et al., Inflammatory response in ventilated left and collapsed right lungs, serum and pleural fluid, in transthoracic esophagectomy for cancer. Eur Cytokine Netw, 2010. 21(1): p. 50-7.

257. Michelet, P., et al., Protective ventilation influences systemic inflammation after esophagectomy: a randomized controlled study. Anesthesiology, 2006. 105(5): p. 911-9.

258. Nakazawa, K., et al., Effect of prostaglandin E1 on inflammatory responses and gas exchange in patients undergoing surgery for oesophageal cancer. Br J Anaesth, 2004. 93(2): p. 199-203.

259. Engelman, E. and C. Maeyens, Effect of preoperative single-dose corticosteroid administration on postoperative morbidity following esophagectomy. J Gastrointest Surg, 2010. 14(5): p. 788-804.

260. Chandrashekar, M.V., et al., Immediate extubation and epidural analgesia allow safe management in a high-dependency unit after two-stage oesophagectomy. Results of eight years of experience in a specialized upper gastrointestinal unit in a district general hospital. Br J Anaesth, 2003. 90(4): p. 474-9.

261. Yap, F.H., et al., Early extubation after transthoracic oesophagectomy. Hong Kong Med J, 2003. 9(2): p. 98-102.

262. Oohashi, S. and H. Endoh, Does central venous pressure or pulmonary capillary wedge pressure reflect the status of circulating blood volume in patients after extended transthoracic esophagectomy? J Anesth, 2005. 19(1): p. 21-5.

263. Wei, S., et al., Association of perioperative fluid balance and adverse surgical outcomes in esophageal cancer and esophagogastric junction cancer. Ann Thorac Surg, 2008. 86(1): p. 266-72.

264. Tandon, S., et al., Peri-operative risk factors for acute lung injury after elective oesophagectomy. Br J Anaesth, 2001. 86(5): p. 633-8.

265. Zingg, U., et al., Factors associated with postoperative pulmonary morbidity after esophagectomy for cancer. Ann Surg Oncol, 2011. 18(5): p. 1460-8.

266. Michelet, P., et al., Non-invasive ventilation for treatment of postoperative respiratory failure after oesophagectomy. Br J Surg, 2009. 96(1): p. 54-60.

267. Murthy, S.C., et al., Atrial fibrillation after esophagectomy is a marker for postoperative morbidity and mortality. J Thorac Cardiovasc Surg, 2003. 126(4): p. 1162-7.

268. Kimura, T., et al., Alterations in spectral characteristics of heart rate variability as a correlate of cardiac autonomic dysfunction after esophagectomy or pulmonary resection. Anesthesiology, 1996. 84(5): p. 1068-76.

269. Amar, D., et al., Symptomatic tachydysrhythmias after esophagectomy: incidence and outcome measures. Ann Thorac Surg, 1996. 61(5): p. 1506-9.

270. Tisdale, J.E., et al., A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. J Thorac Cardiovasc Surg, 2010. 140(1): p. 45-51.

271. Ahn, H.J., et al., Thoracic epidural anesthesia does not improve the incidence of arrhythmias after transthoracic esophagectomy. Eur J Cardiothorac Surg, 2005. 28(1): p. 19-21.

272. Davies, L. and H.G. Welch, Epidemiology of head and neck cancer in the United States. Otolaryngol Head Neck Surg, 2006. 135(3): p. 451-7.

273. Popescu, C.R., et al., The epidemiology of hypopharynx and cervical esophagus cancer. J Med Life, 2010. 3(4): p. 396-401.

274. Daiko, H., et al., Surgical management of carcinoma of the cervical esophagus. J Surg Oncol, 2007. 96(2): p. 166-72.

275. Triboulet, J.P., et al., Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases. Arch Surg, 2001. 136(10): p. 1164-70.

276. Wang, H.W., et al., A reappraisal of surgical management for squamous cell carcinoma in the pharyngoesophageal junction. J Surg Oncol, 2006. 93(6): p. 468-76.

277. Boone, J., et al., International survey on esophageal cancer: part I surgical techniques. Dis Esophagus, 2009. 22(3): p. 195-202.

278. Boone, J., et al., International survey on esophageal cancer: part II staging and neoadjuvant therapy. Dis Esophagus, 2009. 22(3): p. 203-10.

279. Courrech Staal, E.F., et al., Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg, 2010. 97(10): p. 1482-96.

280. Disa, J.J., A.L. Pusic, and B.J. Mehrara, Reconstruction of the hypopharynx with the free jejunum transfer. J Surg Oncol, 2006. 94(6): p. 466-70.

281. Ferahkose, Z., et al., Comparison of free jejunal graft with gastric pull-up reconstruction after resection of hypopharyngeal and cervical esophageal carcinoma. Dis Esophagus, 2008. 21(4): p. 340-5.

282. Ikeguchi, M., et al., Free jejunal graft reconstruction after resection of neck cancers: our surgical technique. Surg Today, 2009. 39(11): p. 925-8.

283. Nishimura, K., et al., Pharyngolaryngeal reflux in patients who underwent cervical esophago-gastrostomy following esophagectomy. Dis Esophagus, 2010. 23(5): p. 353-60.

284. Ott, K., et al., Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus. Br J Surg, 2009. 96(3): p. 258-66.

285. Uno, T., et al., Concurrent chemoradiation for patients with squamous cell carcinoma of the cervical esophagus. Dis Esophagus, 2007. 20(1): p. 12-8.

286. Yamada, K., et al., Treatment results of radiotherapy for carcinoma of the cervical esophagus. Acta Oncol, 2006. 45(8): p. 1120-5.

287. Zhao, D., et al., Free jejunal graft for reconstruction of defects in the hypopharynx and cervical esophagus following the cancer resections. J Gastrointest Surg, 2009. 13(7): p. 1368-72.

288. Liao, Z., et al., Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys, 2004. 60(5): p. 1484-93.

289. Ruhstaller, T., et al., Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). Onkologie, 2010. 33(5): p. 222-8.

290. Timon, C.I., M.A. Walsh, and T.P. Hennessy, Surgical treatment of hypopharyngeal tumours. J R Coll Surg Edinb, 1991. 36(2): p. 113-6.

291. Nakatsuka, T., et al., Comparative evaluation in pharyngo-oesophageal reconstruction: radial forearm flap compared with jejunal flap. A 10-year experience. Scand J Plast Reconstr Surg Hand Surg, 1998. 32(3): p. 307-10.

292. Schilling, M.K., et al., Long-term survival of patients with stage IV hypopharyngeal cancer: impact of fundus rotation gastroplasty. World J Surg, 2002. 26(5): p. 561-5.

293. Ullah, R., et al., Pharyngo-laryngo-oesophagectomy and gastric pull-up for post-cricoid and cervical oesophageal squamous cell carcinoma. J Laryngol Otol, 2002. 116(10): p. 826-30.

294. Oniscu, G.C., W.S. Walker, and R. Sanderson, Functional results following pharyngolaryngooesophagectomy with free jejunal graft reconstruction. Eur J Cardiothorac Surg, 2001. 19(4): p. 406-10.

295. Laterza, E., et al., Primary carcinoma of the hypopharynx and cervical esophagus: evolution of surgical therapy. Hepatogastroenterology, 1994. 41(3): p. 278-82.

296. Jones, A.S., et al., Free revascularized jejunal loop repair following total pharyngolaryngectomy for carcinoma of the hypopharynx: report of 90 patients. Br J Surg, 1996. 83(9): p. 1279-3.

297. Ferguson, J.L. and L.W. DeSanto, Total pharyngolaryngectomy and cervical esophagectomy with jejunal autotransplant reconstruction: complications and results. Laryngoscope, 1988. 98(9): p. 911-4.

298. Shirakawa, Y., et al., Free jejunal graft for hypopharyngeal and esophageal reconstruction. Langenbecks Arch Surg, 2004. 389(5): p. 387-90.

299. Bergquist, H., Aspects on the management of patients with esophageal cancer. Göteborg University. Sahlgrenska Academy, 2007.

300. Walther, B., et al., Cervical or thoracic anastomosis after esophageal resection and gastric tube reconstruction: a prospective randomized trial comparing sutured neck anastomosis with stapled intrathoracic anastomosis. Ann Surg, 2003. 238(6): p. 803-12; discussion 812-4.

301. Orringer, M.B., et al., Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg, 2007. 246(3): p. 363-72; discussion 372-4.

302. Nishihira, T., K. Hirayama, and S. Mori, A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg, 1998. 175(1): p. 47-51.

303. AJCC, Cancer Staging Handbook; seventh edition. 2010.

304. Hulscher, J.B., et al., Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med, 2002. 347(21): p. 1662-9.

305. Omloo, J.M., et al., Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg, 2007. 246(6): p. 992-1000; discussion 1000-1.

306. Johansson, J., et al., Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction. World J Surg, 2008. 32(6): p. 1013-20.

307. Bozzetti, F., Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. Support Care Cancer, 2009. 17(3): p. 279-84.

308. Bozzetti, F., et al., Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg, 1999. 230(2): p. 170-8.

309. Gouzi, J.L., et al., Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg, 1989. 209(2): p. 162-6.

310. Davies, J., et al., Total or subtotal gastrectomy for gastric carcinoma? A study of quality of life. World J Surg, 1998. 22(10): p. 1048-55.

311. Zilling, T.L., et al., Prediction of survival in gastric carcinoma and a new histopathologic approach. Anticancer Res, 1989. 9(2): p. 487-99.

312. Maruyama, K., et al., Surgical treatment for gastric cancer: the Japanese approach. Semin Oncol, 1996. 23(3): p. 360-8.

313. Olbe, L. and L. Lundell, Intestinal function after total gastrectomy and possible consequences of gastric replacement. World J Surg, 1987. 11(6): p. 713-9.

314. Zilling, T., et al., Nutritional state, growth rate, and morphology after total gastrectomy with restoration of duodenal passage or Roux-en-Y oesophagojejunostomy with or without a pouch: an experimental study in pigs. Eur J Surg, 1998. 164(5): p. 377-84.

315. Bonenkamp, J.J., et al., Extended lymph-node dissection for gastric cancer. N Engl J Med, 1999. 340(12): p. 908-14.

316. Hartgrink, H.H., et al., Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol, 2004. 22(11): p. 2069-77.

317. Cuschieri, A., et al., Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet, 1996. 347(9007): p. 995-9.

318. Cuschieri, A., et al., Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer, 1999. 79(9-10): p. 1522-30.

319. Wu, C.W., et al., Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncology, 2006. 7(4): p. 309-15.

320. Sasako, M., et al., D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med, 2008. 359(5): p. 453-62.

321. McCulloch, P., et al., Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev, 2003(4): p. CD001964.

322. Degiuli, M., M. Sasako, and A. Ponti, Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg, 2010. 97(5): p. 643-9.

323. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer, 2011. 14(2): p. 113-123.

324. Sano, T. and T. Aiko, New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer, 2011. 14(2): p. 97-100.

325. Lo, S.S., et al., Higher morbidity and mortality after combined total gastrectomy and pancreaticosplenectomy for gastric cancer. World J Surg, 2002. 26(6): p. 678-82.

326. Sano, T., S. Yamamoto, and M. Sasako, Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF. Jpn J Clin Oncol, 2002. 32(9): p. 363-4.

327. Fujita, J., et al., Survival benefit of bursectomy in patients with resectable gastric cancer: interim analysis results of a randomized controlled trial. Gastric Cancer, 2012. 15(1): p. 42-8.

328. Anon, The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc, 2003. 58(6 Suppl): p. S3-43.

329. Stein, H.J., et al., Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg, 2005. 242(4): p. 566-73; discussion 573-5.

330. Liu, L., et al., Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol, 2005. 29(8): p. 1079-85.

331. Westerterp, M., et al., Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch, 2005. 446(5): p. 497-504.

332. Falk, G.W., et al., Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc, 1999. 49(2): p. 170-6.

333. Reed, M.F., et al., Surgical treatment of esophageal high-grade dysplasia. Ann Thorac Surg, 2005. 79(4): p. 1110-5; discussion 1110-5.

334. Konda, V.J., et al., Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin Gastroenterol Hepatol, 2008. 6(2): p. 159-64.

335. Urabe, Y., et al., Metachronous multiple esophageal squamous cell carcinomas and Lugol-voiding lesions after endoscopic mucosal resection. Endoscopy, 2009. 41(4): p. 304-9.

336. Shimizu, Y., et al., Long-term outcome after endoscopic mucosal resection in patients with esophageal squamous cell carcinoma invading the muscularis mucosae or deeper. Gastrointest Endosc, 2002. 56(3): p. 387-90.

337. Wolfsen, H.C., L.L. Hemminger, and K.R. DeVault, Recurrent Barrett's esophagus and adenocarcinoma after esophagectomy. BMC Gastroenterol, 2004. 4: p. 18.

338. Ono, H., et al., Endoscopic mucosal resection for treatment of early gastric cancer. Gut, 2001. 48(2): p. 225-9.

339. Ell, C., et al., Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc, 2007. 65(1): p. 3-10.

340. Schnell, T.G., et al., Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology, 2001. 120(7): p. 1607-19.

341. May, A., et al., Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol, 2002. 14(10): p. 1085-91.

342. Hornick, J.L., et al., Buried Barrett's epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities. Am J Gastroenterol, 2008. 103(1): p. 38-47.

343. Shaheen, N.J., et al., Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med, 2009. 360(22): p. 2277-88.

344. Pech, O., et al., Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut, 2008. 57(9): p. 1200-6.

345.      Shimizu, Y., et al., Endoscopic clip application for closure of esophageal perforations caused by EMR. Gastrointest Endosc, 2004. 60(4): p. 636-9.

346.      Tsunada, S., et al., Endoscopic closure of perforations caused by EMR in the stomach by application of metallic clips. Gastrointest Endosc, 2003. 57(7): p. 948-51.

347. Giovannini, M., et al., Circumferential endoscopic mucosal resection in Barrett's esophagus with high-grade intraepithelial neoplasia or mucosal cancer. Preliminary results in 21 patients. Endoscopy, 2004. 36(9): p. 782-7.

348. Peters, F.P., et al., Stepwise radical endoscopic resection is effective for complete removal of Barrett's esophagus with early neoplasia: a prospective study. Am J Gastroenterol, 2006. 101(7): p. 1449-57.

349. Hage, M., et al., Molecular evaluation of ablative therapy of Barrett's oesophagus. J Pathol, 2005. 205(1): p. 57-64.

350. Greenstein, A.J., J.P. Wisnivesky, and V.R. Litle, Effect of local therapy for the treatment of superficial esophageal cancer in non-operative candidates. Dis Esophagus, 2008. 21(8): p. 673-8.

351. Das, A., et al., A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. Am J Gastroenterol, 2008. 103(6): p. 1340-5.

352. Pacifico, R.J., et al., Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol, 2003. 1(4): p. 252-7.

353. Prasad, G.A., et al., Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology, 2007. 132(4): p. 1226-33.

354. Schembre, D.B., et al., Treatment of Barrett's esophagus with early neoplasia: a comparison of endoscopic therapy and esophagectomy. Gastrointest Endosc, 2008. 67(4): p. 595-601.

355. Yachimski, P., et al., Treatment of Barrett's esophagus with high-grade dysplasia or cancer: predictors of surgical versus endoscopic therapy. Clin Gastroenterol Hepatol, 2008. 6(11): p. 1206-11.

356. Gotoda, T., et al., Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer, 2000. 3(4): p. 219-225.

357. Yamao, T., et al., Risk factors for lymph node metastasis from intramucosal gastric carcinoma. Cancer, 1996. 77(4): p. 602-6.

358. Kojima, T., et al., Outcome of endoscopic mucosal resection for early gastric cancer: review of the Japanese literature. Gastrointest Endosc, 1998. 48(5): p. 550-4; discussion 554-5.

359. Tada, M., et al., Mucosectomy for gastric cancer: current status in Japan. J Gastroenterol Hepatol, 2000. 15 Suppl: p. D98-102.

360. Uedo, N., et al., Longterm outcomes after endoscopic mucosal resection for early gastric cancer. Gastric Cancer, 2006. 9(2): p. 88-92.

361. Giovannini, M., et al., Endoscopic mucosal resection (EMR): results and prognostic factors in 21 patients. Endoscopy, 1999. 31(9): p. 698-701.

362. Oda, I., et al., A multicenter retrospective study of endoscopic resection for early gastric cancer. Gastric Cancer, 2006. 9(4): p. 262-70.

363. Kondo, H., et al., Early gastric cancer: endoscopic mucosal resection. Ann Ital Chir, 2001. 72(1): p. 27-31.

364. Miyata, M., et al., What are the appropriate indications for endoscopic mucosal resection for early gastric cancer? Analysis of 256 endoscopically resected lesions. Endoscopy, 2000. 32(10): p. 773-8.

365. Watanabe, Y., et al., Safer endoscopic gastric mucosal resection: preoperative proton pump inhibitor administration. J Gastroenterol Hepatol, 2006. 21(11): p. 1675-80.

366. Kim, H.S., et al., Endoscopic mucosal resection with a ligation device for early gastric cancer and precancerous lesions: comparison of its therapeutic efficacy with surgical resection. Yonsei Med J, 2000. 41(5): p. 577-83.

367. Nishida, T., et al., [Comparison of endoscopic therapy and conventional surgery for the treatment of early gastric cancer in elderly patients]. Nihon Ronen Igakkai Zasshi, 1993. 30(5): p. 376-81.

368. Charoenkwan, K., G. Phillipson, and T. Vutyavanich, Early versus delayed (traditional) oral fluids and food for reducing complications after major abdominal gynaecologic surgery. Cochrane Database Syst Rev, 2007(4): p. CD004508.

369. Hirao, M., et al., Patient-controlled dietary schedule improves clinical outcome after gastrectomy for gastric cancer. World J Surg, 2005. 29(7): p. 853-7.

370. Markides, G.A., B. Alkhaffaf, and J. Vickers, Nutritional access routes following oesophagectomy--a systematic review. Eur J Clin Nutr, 2011. 65(5): p. 565-73.

371. Fenton, J.R., et al., Feeding jejunostomy tubes placed during esophagectomy: are they necessary? Ann Thorac Surg, 2011. 92(2): p. 504-11; discussion 511-2.

372. Cerfolio, R.J., et al., Fast tracking after Ivor Lewis esophagogastrectomy. Chest, 2004. 126(4): p. 1187-94.

373. Munitiz, V., et al., Effectiveness of a written clinical pathway for enhanced recovery after transthoracic (Ivor Lewis) oesophagectomy. Br J Surg, 2010. 97(5): p. 714-8.

374. Tomaszek, S.C., et al., An alternative postoperative pathway reduces length of hospitalisation following oesophagectomy. Eur J Cardiothorac Surg, 2010. 37(4): p. 807-13.

375. Liu, X.X., et al., Multimodal optimization of surgical care shows beneficial outcome in gastrectomy surgery. JPEN J Parenter Enteral Nutr, 2010. 34(3): p. 313-21.

376. Wang, D., et al., Fast-track surgery improves postoperative recovery in patients with gastric cancer: a randomized comparison with conventional postoperative care. J Gastrointest Surg, 2010. 14(4): p. 620-7.

377. Grantcharov, T.P. and H. Kehlet, Laparoscopic gastric surgery in an enhanced recovery programme. Br J Surg, 2010. 97(10): p. 1547-51.

378. Yang, Z., Q. Zheng, and Z. Wang, Meta-analysis of the need for nasogastric or nasojejunal decompression after gastrectomy for gastric cancer. Br J Surg, 2008. 95(7): p. 809-16.

379. Nelson, R., S. Edwards, and B. Tse, Prophylactic nasogastric decompression after abdominal surgery. Cochrane Database Syst Rev, 2007(3): p. CD004929.

380. Daryaei, P., et al., Omission of nasogastric tube application in postoperative care of esophagectomy. World J Surg, 2009. 33(4): p. 773-7.

381. Miyazaki, T., et al., Predictive value of blood flow in the gastric tube in anastomotic insufficiency after thoracic esophagectomy. World J Surg, 2002. 26(11): p. 1319-23.

382. Tonouchi, H., et al., Diagnostic sensitivity of contrast swallow for leakage after gastric resection. World J Surg, 2007. 31(1): p. 128-31.

383. Strauss, C., et al., Computed tomography versus water-soluble contrast swallow in the detection of intrathoracic anastomotic leak complicating esophagogastrectomy (Ivor Lewis): a prospective study in 97 patients. Ann Surg, 2010. 251(4): p. 647-51.

384. Upponi, S., et al., Radiological detection of post-oesophagectomy anastomotic leak - a comparison between multidetector CT and fluoroscopy. Br J Radiol, 2008. 81(967): p. 545-8.

385. Bohner, H., et al., Detection and prognosis of recurrent gastric cancer--is routine follow-up after gastrectomy worthwhile? Hepatogastroenterology, 2000. 47(35): p. 1489-94.

386. Eom, B.W., et al., Oncologic effectiveness of regular follow-up to detect recurrence after curative resection of gastric cancer. Ann Surg Oncol, 2011. 18(2): p. 358-64.

387. Kodera, Y., et al., Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol, 2003. 10(8): p. 898-902.

388. Lee, J.E., et al., The role of 18F-FDG PET/CT in the evaluation of gastric cancer recurrence after curative gastrectomy. Yonsei Med J, 2011. 52(1): p. 81-8.

389. Fukase, K., et al., Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet, 2008. 372(9636): p. 392-7.

390. Hosokawa, O., et al., Endoscopic surveillance for gastric remnant cancer after early cancer surgery. Endoscopy, 2002. 34(6): p. 469-73.

391. Johansson, J., et al., Impact of proton pump inhibitors on benign anastomotic stricture formations after esophagectomy and gastric tube reconstruction: results from a randomized clinical trial. Ann Surg, 2009. 250(5): p. 667-73.

392. Prodan, C.I., et al., Copper deficiency after gastric surgery: a reason for caution. Am J Med Sci, 2009. 337(4): p. 256-8.

393. Rino, Y., et al., Vitamin E malabsorption and neurological consequences after gastrectomy for gastric cancer. Hepatogastroenterology, 2007. 54(78): p. 1858-61.

394. Ueda, N., et al., Correlation between neurological dysfunction with vitamin E deficiency and gastrectomy. J Neurol Sci, 2009. 287(1-2): p. 216-20.

395. Verschuur, E.M., et al., Nurse-led follow-up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. Br J Cancer, 2009. 100(1): p. 70-6.

396. Ehrenberg, A., M. Ehnfors, and I. Thorell-Ekstrand, The VIPS model--implementation and validity in different areas of nursing care. Stud Health Technol Inform, 1997. 46: p. 408-10.

397. Viklund, P. and J. Lagergren, A care pathway for patients with oesophageal cancer. Eur J Cancer Care (Engl), 2007. 16(6): p. 533-8.

398. Derogar, M. and P. Lagergren, Health-Related Quality of Life Among 5-Year Survivors of Esophageal Cancer Surgery: A Prospective Population-Based Study. J Clin Oncol, 2012.

399. Martin, L. and P. Lagergren, Long-term weight change after oesophageal cancer surgery. Br J Surg, 2009. 96(11): p. 1308-14.

400. Adamsen, L., et al., Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ, 2009. 339: p. b3410.

401. Quist, M., et al., High-intensity resistance and cardiovascular training improve physical capacity in cancer patients undergoing chemotherapy. Scand J Med Sci Sports, 2006. 16(5): p. 349-57.

402. Fagevik-Olsén, M., Chest physical therapy in surgery. A theoretical model about who to treat. Breathe, 2005(1): p. 308-14.

403. Brooks-Brunn, J.A., Predictors of postoperative pulmonary complications following abdominal surgery. Chest, 1997. 111(3): p. 564-71.

404. Olséni-och-Wollmer, ed. Sjukgymnastik vid nedsatt lungfunktion. 2002, Studentlitteratur: Lund.

405. Antonsson, M., et al., Riktlinjer för andningsvårdande behandling inom sjukgymnastik för patienter som genomgår buk- och thoraxkirurgi LSR. www.lsr.se. 2009.

406. Fagevik Olsen, M., et al., Physical function and quality of life after thoracoabdominal oesophageal resection. Results of a follow-up study. Dig Surg, 2005. 22(1-2): p. 63-8.

407. Olsen, M.F., et al., Procedure-related chronic pain after thoracoabdominal resection of the esophagus. Physiother Theory Pract, 2009. 25(7): p. 489-94.

408. Viklund, P., Y. Wengstrom, and J. Lagergren, Supportive care for patients with oesophageal and other upper gastrointestinal cancers: The role of a specialist nurse in the team. Eur J Oncol Nurs, 2006. 10(5): p. 353-63.

409. Wells, M., et al., A study to evaluate nurse-led on-treatment review for patients undergoing radiotherapy for head and neck cancer. J Clin Nurs, 2008. 17(11): p. 1428-39.

410. Blazeby, J.M., et al., A prospective comparison of quality of life measures for patients with esophageal cancer. Qual Life Res, 2005. 14(2): p. 387-93.

411. Wildi, S.M., et al., Assessment of health state utilities and quality of life in patients with malignant esophageal Dysphagia. Am J Gastroenterol, 2004. 99(6): p. 1044-9.

412. Adam, A., et al., Palliation of inoperable esophageal carcinoma: a prospective randomized trial of laser therapy and stent placement. Radiology, 1997. 202(2): p. 344-8.

413. Cantero, R., et al., Palliative treatment of esophageal cancer: self-expanding metal stents versus Postlethwait technique. Hepatogastroenterology, 1999. 46(26): p. 971-6.

414. Dallal, H.J., et al., A randomized trial of thermal ablative therapy versus expandable metal stents in the palliative treatment of patients with esophageal carcinoma. Gastrointest Endosc, 2001. 54(5): p. 549-57.

415. De Palma, G.D., et al., Plastic prosthesis versus expandable metal stents for palliation of inoperable esophageal thoracic carcinoma: a controlled prospective study. Gastrointest Endosc, 1996. 43(5): p. 478-82.

416. Knyrim, K., et al., A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med, 1993. 329(18): p. 1302-7.

417. Lundell, L., et al., Palliative endoscopic dilatation in carcinoma of the esophagus and esophagogastric junction. Acta Chir Scand, 1989. 155(3): p. 179-84.

418. Siersema, P.D., et al., Coated self-expanding metal stents versus latex prostheses for esophagogastric cancer with special reference to prior radiation and chemotherapy: a controlled, prospective study. Gastrointest Endosc, 1998. 47(2): p. 113-20.

419. Bergquist, H., et al., Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus, 2005. 18(3): p. 131-9.

420. Homs, M.Y., et al., Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet, 2004. 364(9444): p. 1497-504.

421. Wenger, U., et al., Health economic evaluation of stent or endoluminal brachytherapy as a palliative strategy in patients with incurable cancer of the oesophagus or gastro-oesophageal junction: results of a randomized clinical trial. Eur J Gastroenterol Hepatol, 2005. 17(12): p. 1369-77.

422. Conio, M., et al., A randomized prospective comparison of self-expandable plastic stents and partially covered self-expandable metal stents in the palliation of malignant esophageal dysphagia. Am J Gastroenterol, 2007. 102(12): p. 2667-77.

423. Sabharwal, T., et al., Randomised comparison of the FerX Ella antireflux stent and the ultraflex stent: proton pump inhibitor combination for prevention of post-stent reflux in patients with esophageal carcinoma involving the esophago-gastric junction. J Gastroenterol Hepatol, 2008. 23(5): p. 723-8.

424. Verschuur, E.M., et al., New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: a randomized trial. Am J Gastroenterol, 2008. 103(2): p. 304-12.

425. Golder, M., et al., Chest pain following oesophageal stenting for malignant dysphagia. Clin Radiol, 2001. 56(3): p. 202-5.

426. Profili, S., et al., Self-expandable metal stents in the management of cervical oesophageal and/or hypopharyngeal strictures. Clin Radiol, 2002. 57(11): p. 1028-33.

427. Verschuur, E.M., E.J. Kuipers, and P.D. Siersema, Esophageal stents for malignant strictures close to the upper esophageal sphincter. Gastrointest Endosc, 2007. 66(6): p. 1082-90.

428. Siersema, P.D., et al., A comparison of 3 types of covered metal stents for the palliation of patients with dysphagia caused by esophagogastric carcinoma: a prospective, randomized study. Gastrointest Endosc, 2001. 54(2): p. 145-53.

429. Vakil, N., et al., A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol, 2001. 96(6): p. 1791-6.

430. Blomberg, J., et al., Antireflux stent versus conventional stent in the palliation of distal esophageal cancer. A randomized, multicenter clinical trial. Scand J Gastroenterol, 2010. 45(2): p. 208-16.

431. Shim, C.S., et al., Management of malignant stricture of the esophagogastric junction with a newly designed self-expanding metal stent with an antireflux mechanism. Endoscopy, 2005. 37(4): p. 335-9.

432. Shin, J.H., et al., Esophagorespiratory fistula: long-term results of palliative treatment with covered expandable metallic stents in 61 patients. Radiology, 2004. 232(1): p. 252-9.

433. Agustsson, T., et al., Treatment of postoperative esophagorespiratory fistulas with dual self-expanding metal stents. World J Surg, 2009. 33(6): p. 1224-8.

434. Volkmer, K., et al., [Metastasis of an esophageal carcinoma at a PEG site--case report and review of the literature]. Zentralbl Chir, 2009. 134(5): p. 481-5.

435. Bower, M., et al., Nutritional support with endoluminal stenting during neoadjuvant therapy for esophageal malignancy. Ann Surg Oncol, 2009. 16(11): p. 3161-8.

436. Hunerbein, M., et al., Treatment of thoracic anastomotic leaks after esophagectomy with self-expanding plastic stents. Ann Surg, 2004. 240(5): p. 801-7.

437. Del Piano, M., et al., Endoscopy or surgery for malignant GI outlet obstruction? Gastrointest Endosc, 2005. 61(3): p. 421-6.

438. Jeurnink, S.M., et al., Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointest Endosc, 2010. 71(3): p. 490-9.

439. Johnsson, E., A. Thune, and B. Liedman, Palliation of malignant gastroduodenal obstruction with open surgical bypass or endoscopic stenting: clinical outcome and health economic evaluation. World J Surg, 2004. 28(8): p. 812-7.

440. Mehta, S., et al., Prospective randomized trial of laparoscopic gastrojejunostomy versus duodenal stenting for malignant gastric outflow obstruction. Surg Endosc, 2006. 20(2): p. 239-42.

441. Cho, Y.K., et al., Clinical outcomes of self-expandable metal stent and prognostic factors for stent patency in gastric outlet obstruction caused by gastric cancer. Dig Dis Sci, 2010. 55(3): p. 668-74.

442. Kim, C.G., et al., Covered versus uncovered self-expandable metallic stents for palliation of malignant pyloric obstruction in gastric cancer patients: a randomized, prospective study. Gastrointest Endosc, 2010. 72(1): p. 25-32.

443. Kim, T.O., et al., Self-expandable metallic stents for palliation of patients with malignant gastric outlet obstruction caused by stomach cancer. World J Gastroenterol, 2007. 13(6): p. 916-20.

444. Lee, K.M., et al., Palliative treatment of malignant gastroduodenal obstruction with metallic stent: prospective comparison of covered and uncovered stents. Scand J Gastroenterol, 2009. 44(7): p. 846-52.

445. Shin, J.H., Interventional management of tracheobronchial strictures. World J Radiol, 2010. 2(8): p. 323-8.

446. Sihoe, A.D., I.Y. Wan, and A.P. Yim, Airway stenting for unresectable esophageal cancer. Surg Oncol, 2004. 13(1): p. 17-25.

447. Morita, M., et al., In-hospital mortality after a surgical resection for esophageal cancer: analyses of the associated factors and historical changes. Ann Surg Oncol, 2011. 18(6): p. 1757-65.

448. Sundelof, M., J. Lagergren, and W. Ye, Patient demographics and lifestyle factors influencing long-term survival of oesophageal cancer and gastric cardia cancer in a nationwide study in Sweden. Eur J Cancer, 2008. 44(11): p. 1566-71.

449. Whooley, B.P., et al., The Kirschner operation in unresectable esophageal cancer: current application. Arch Surg, 2002. 137(11): p. 1228-32.

450. Hartgrink, H.H., et al., Value of palliative resection in gastric cancer. Br J Surg, 2002. 89(11): p. 1438-43.

451. Huang, K.H., et al., Palliative resection in noncurative gastric cancer patients. World J Surg, 2010. 34(5): p. 1015-21.

452. Wang, C.S., et al., Benefits of palliative surgery for far-advanced gastric cancer. Chang Gung Med J, 2002. 25(12): p. 792-802.

453. Kim, D.Y., et al., Is palliative resection necessary for gastric carcinoma patients? Langenbecks Arch Surg, 2008. 393(1): p. 31-5.

454. Ouchi, K., et al., Therapeutic significance of palliative operations for gastric cancer for survival and quality of life. J Surg Oncol, 1998. 69(1): p. 41-4.

455. Asakura, H., et al., Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate? J Cancer Res Clin Oncol, 2011. 137(1): p. 125-30.

456. Mittal, A., et al., Matched study of three methods for palliation of malignant pyloroduodenal obstruction. Br J Surg, 2004. 91(2): p. 205-9.

457. Osorio, J., et al., Outcome of unresected gastric cancer after laparoscopic diagnosis of peritoneal carcinomatosis. Clin Transl Oncol, 2008. 10(5): p. 294-7.

458. Sarela, A.I., et al., Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma. Ann Surg, 2006. 243(2): p. 189-95.

459. Sarela, A.I. and S. Yelluri, Gastric adenocarcinoma with distant metastasis: is gastrectomy necessary? Arch Surg, 2007. 142(2): p. 143-9; discussion 149.

460. Miner, T.J., et al., Defining palliative surgery in patients receiving noncurative resections for gastric cancer. J Am Coll Surg, 2004. 198(6): p. 1013-21.

461. Boyce, Palliation of Dysphagia of Esophageal Cancer by Endoscopic Lumen Restoration Techniques. Cancer Control. , 1999. (1)(Jan;6:): p. 73-83.

462. Caspers RJ, W.K., Verkes RJ, Hermans J, Leer JW., The effect of radiotherapy on dysphagia and survival in patients with esophageal cancer. Radiother Oncol. , 1988. (1)(May;12): p. 15-23.

463.      Sur RK, S.D., Sharma SC, Singh MT, Kochhar R, Negi PS, Sethi T, Patel F, Ayyagari S, Bhatia SP, et al., Radiation therapy of esophageal cancer: role of high dose rate brachytherapy. Int J Radiat Oncol Biol Phys. , 1992. (5)(22): p. 1043-6.

464. Sur, R., et al., Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer. Brachytherapy, 2004. 3(4): p. 191-195.

465. Rosenblatt, E., et al., Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: A prospective multi-centre randomized trial of the International Atomic Energy Agency. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 97(3): p. 488-494.

466. Sur, R.K., et al., Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma—an International Atomic Energy Agency study. International journal of radiation oncology, biology, physics, 2002. 53(1): p. 127-133.

467. Homs, M.Y.V., et al., Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. The Lancet, 2004. 364(9444): p. 1497-1504.

468.  Homs, M.Y.V., et al., Quality of life after palliative treatment for oesophageal carcinoma – a prospective comparison between stent placement and single dose brachytherapy. European journal of cancer (Oxford, England : 1990), 2004. 40(12): p. 1862-1871.

469. Homs MY, v.d.G.A., Siersema PD, Steyerberg EW, Kuipers EJ., Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev. , 2006. (4)(Oct 18): p. CD004063.

470. Boyce, H.W., Jr., Palliation of Dysphagia of Esophageal Cancer by Endoscopic Lumen Restoration Techniques. Cancer Control, 1999. 6(1): p. 73-83.

471. Thompson, A.M., et al., Endoscopic palliative treatment for esophageal and gastric cancer: techniques, complications, and survival in a population-based cohort of 948 patients. Surg Endosc, 2004. 18(8): p. 1257-62.

472. Caspers, R.J., et al., The effect of radiotherapy on dysphagia and survival in patients with esophageal cancer. Radiother Oncol, 1988. 12(1): p. 15-23.

473. Sur, R.K., et al., Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma--an International Atomic Energy Agency study. Int J Radiat Oncol Biol Phys, 2002. 53(1): p. 127-33.

474. Sur, R., et al., Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer. Brachytherapy, 2004. 3(4): p. 191-5.

475. Rosenblatt, E., et al., Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: a prospective multi-centre randomized trial of the International Atomic Energy Agency. Radiother Oncol, 2010. 97(3): p. 488-94.

476. Sur, R.K., et al., Radiation therapy of esophageal cancer: role of high dose rate brachytherapy. Int J Radiat Oncol Biol Phys, 1992. 22(5): p. 1043-6.

477. Glimelius, B., et al., Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 1997. 8(2): p. 163-8.

478. Murad, A.M., et al., Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer, 1993. 72(1): p. 37-41.

479. Pyrhonen, S., et al., Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer, 1995. 71(3): p. 587-91.

480. Scheithauer, W., T. Schenk, and M. Czejka, Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil. Br J Cancer, 1993. 68(1): p. 8-9.

481. Scheithauer, W.K., F. Zek, B et al., Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer: A randomized trial. . Second Int Conf Biol, Prev, Treatm GI Malignancy, Koln, Germany 1995: p. 1995;68 (Abstr).

482. Webb, A., et al., Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol, 1997. 15(1): p. 261-7.

483. Moehler, M., et al., Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer, 2005. 92(12): p. 2122-8.

484. Pozzo, C., et al., Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol, 2004. 15(12): p. 1773-81.

485. Dank, M., et al., Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol, 2008. 19(8): p. 1450-7.

486. Van Cutsem, E., et al., Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 2006. 24(31): p. 4991-7.

487. Kang, Y.K., et al., Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol, 2009. 20(4): p. 666-73.

488. Gubanski, M., et al., Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial. Gastric Cancer, 2010. 13(3): p. 155-61.

489. Wagner, A.D., et al., Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol, 2006. 24(18): p. 2903-9.

490. Thusse-Patience, P., J Clin Oncol 27:15s (suppl;abstr 4540), 2009.

491. Ohtsu, A., et al., Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol, 2011. 29(30): p. 3968-76.

492. Bang, Y.J., et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010. 376(9742): p. 687-97.

493. Persson, C. and B. Glimelius, The relevance of weight loss for survival and quality of life in patients with advanced gastrointestinal cancer treated with palliative chemotherapy. Anticancer Res, 2002. 22(6B): p. 3661-8.

494. Barber, M.D., The pathophysiology and treatment of cancer cachexia. Nutr Clin Pract, 2002. 17(4): p. 203-9.

495. Tisdale, M.J., Cachexia in cancer patients. Nat Rev Cancer, 2002. 2(11): p. 862-71.

496. Fearon, K., et al., Definition and classification of cancer cachexia: an international consensus. Lancet Oncology, 2011. 12(5): p. 489-95.

497. Lundholm, K., et al., Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function. Cancer, 2004. 100(9): p. 1967-77.

498. Shang, E., et al., The influence of early supplementation of parenteral nutrition on quality of life and body composition in patients with advanced cancer. JPEN J Parenter Enteral Nutr, 2006. 30(3): p. 222-30.

499. Lundholm, K., et al., Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol, 2004. 24(3): p. 505-12.

500. Lundholm, K., et al., Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res, 1994. 54(21): p. 5602-6.

501. Dewey, A., et al., Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev, 2007(1): p. CD004597.

502. Colomer, R., et al., N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Br J Nutr, 2007. 97(5): p. 823-31.

503. Yamashita, J.I. and M. Ogawa, Medroxyprogesterone acetate and cancer cachexia: interleukin-6 involvement. Breast Cancer, 2000. 7(2): p. 130-5.

504. Madeddu, C., et al., Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opin Pharmacother, 2009. 10(8): p. 1359-66.

505. Daneryd, P., et al., Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Cancer Res, 1998. 58(23): p. 5374-9.

506. Lundholm, K., et al., Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res, 2007. 13(9): p. 2699-706.

507. Metzger, R., et al., High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality? Dis Esophagus, 2004. 17(4): p. 310-4.

508. Viklund, P., et al., Risk factors for complications after esophageal cancer resection: a prospective population-based study in Sweden. Ann Surg, 2006. 243(2): p. 204-11.

509. Begg, C.B., et al., Impact of hospital volume on operative mortality for major cancer surgery. JAMA, 1998. 280(20): p. 1747-51.

510. Bonenkamp, J.J., Surgery for upper gastrointestinal malignancies. Semin Oncol, 2004. 31(4): p. 542-53.

511. Gordon, T.A., et al., Complex gastrointestinal surgery: impact of provider experience on clinical and economic outcomes. J Am Coll Surg, 1999. 189(1): p. 46-56.

512. Learn, P.A. and P.B. Bach, A decade of mortality reductions in major oncologic surgery: the impact of centralization and quality improvement. Med Care, 2010. 48(12): p. 1041-9.

513. Macdonald, J.S., Gastric cancer: Nagoya is not New York. J Clin Oncol, 2011. 29(33): p. 4348-50.

514. Nomura, E., et al., Population-based study of relationship between hospital surgical volume and 5-year survival of stomach cancer patients in Osaka, Japan. Cancer Sci, 2003. 94(11): p. 998-1002.

515. Sasako, M., et al., Surgical treatment of advanced gastric cancer: Japanese perspective. Dig Surg, 2007. 24(2): p. 101-7.

516. Songun, I. and C.J. van de Velde, Optimal surgery for advanced gastric cancer. Expert Rev Anticancer Ther, 2009. 9(12): p. 1849-58.

517. Birkmeyer, J.D., et al., Hospital volume and surgical mortality in the United States. N Engl J Med, 2002. 346(15): p. 1128-37.

518. Finlayson, E.V. and J.D. Birkmeyer, Effects of hospital volume on life expectancy after selected cancer operations in older adults: a decision analysis. J Am Coll Surg, 2003. 196(3): p. 410-7.

519. Gillison, E.W., et al., Surgical workload and outcome after resection for carcinoma of the oesophagus and cardia. Br J Surg, 2002. 89(3): p. 344-8.

520. Hundahl, S.A., Surgery for gastric cancer: what the trials indicate. Surg Oncol Clin N Am, 2012. 21(1): p. 79-97.

521. Kuo, E.Y., Y. Chang, and C.D. Wright, Impact of hospital volume on clinical and economic outcomes for esophagectomy. Ann Thorac Surg, 2001. 72(4): p. 1118-24.

522. Urbach, D.R., C.M. Bell, and P.C. Austin, Differences in operative mortality between high- and low-volume hospitals in Ontario for 5 major surgical procedures: estimating the number of lives potentially saved through regionalization. CMAJ, 2003. 168(11): p. 1409-14.

523. van de Poll-Franse, L.V., et al., Impact of concentration of oesophageal and gastric cardia cancer surgery on long-term population-based survival. Br J Surg, 2011. 98(7): p. 956-63.

524. van Lanschot, J.J., et al., Hospital volume and hospital mortality for esophagectomy. Cancer, 2001. 91(8): p. 1574-8.

525. Wenner, J., et al., The influence of surgical volume on hospital mortality and 5-year survival for carcinoma of the oesophagus and gastric cardia. Anticancer Res, 2005. 25(1B): p. 419-24.